RYTM - Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc Logo

RYTM - Rhythm Pharmaceuticals Inc

https://rhythmtx.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Uptrend
As of 2025-09-09 (Snapshot)

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic diseases of obesity. The company is headquartered in Boston, Massachusetts.

52W High
$106.52
52W Low
$45.91

MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
2.24
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-12.65
EV/Revenue (<3 favorable)
42.50
P/S (TTM) (<3 favorable)
43.40
P/B (<3 favorable)
224.71
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
0.65%
Institutions (25–75% balanced)
105.10%
Shares Outstanding
66,420,000
Float
54,804,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
156,287,000
Gross Profit (TTM)
139,481,000
EPS (TTM)
-3.01
Profit Margin (>10% good)
-1.17%
Operating Margin (TTM) (higher better)
-0.93%
ROE (TTM) (>15% strong)
-1.17%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
0.67
Momentum
Bearish momentum
Value
2.0377
Previous
2.7263
Trend
Falling
Signal Cross
No cross

As of
Sep. 12, 2025